Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Lung cancer

Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC

Nature Reviews Clinical Oncology volume 22, page 545 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

Patients with extensive-stage small cell lung cancer (ES-SCLC) typically receive first-line combinations of immune-checkpoint inhibitors (ICIs) and platinum-based chemotherapy followed by maintenance ICIs to limit the risk of disease progression. Now, results from the phase III IMforte trial demonstrate that the addition of lurbinectedin to maintenance therapy improves patient outcomes.

A total of 660 patients with an ongoing response or stable disease after first-line therapy were randomly allocated (1:1) to receive maintenance therapy with atezolizumab with or without lurbinectedin. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC. Nat Rev Clin Oncol 22, 545 (2025). https://doi.org/10.1038/s41571-025-01043-9

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-025-01043-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing